- Home
- MRNA vs GTLB Comparison
MRNA vs GTLB Comparison
Compare MRNA & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- GTLB
- Stock Information
- Founded
- MRNA 2010
- GTLB 2011
- Country
- MRNA United States
- GTLB United States
- Employees
- MRNA N/A
- GTLB N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- GTLB EDP Services
- Sector
- MRNA Health Care
- GTLB Technology
- Exchange
- MRNA Nasdaq
- GTLB Nasdaq
- Market Cap
- MRNA 9.8B
- GTLB 8.0B
- IPO Year
- MRNA 2018
- GTLB 2021
- Fundamental
- Price
- MRNA $25.18
- GTLB $48.93
- Analyst Decision
- MRNA Hold
- GTLB Buy
- Analyst Count
- MRNA 15
- GTLB 27
- Target Price
- MRNA $37.15
- GTLB $58.56
- AVG Volume (30 Days)
- MRNA 10.8M
- GTLB 4.4M
- Earning Date
- MRNA 11-06-2025
- GTLB 12-04-2025
- Dividend Yield
- MRNA N/A
- GTLB N/A
- EPS Growth
- MRNA N/A
- GTLB N/A
- EPS
- MRNA N/A
- GTLB N/A
- Revenue
- MRNA $3,078,000,000.00
- GTLB $857,947,000.00
- Revenue This Year
- MRNA N/A
- GTLB $26.43
- Revenue Next Year
- MRNA $11.12
- GTLB $20.11
- P/E Ratio
- MRNA N/A
- GTLB N/A
- Revenue Growth
- MRNA N/A
- GTLB 28.97
- 52 Week Low
- MRNA $23.15
- GTLB $37.90
- 52 Week High
- MRNA $56.70
- GTLB $74.18
- Technical
- Relative Strength Index (RSI)
- MRNA 44.51
- GTLB 54.72
- Support Level
- MRNA $24.25
- GTLB $47.00
- Resistance Level
- MRNA $29.20
- GTLB $49.42
- Average True Range (ATR)
- MRNA 1.50
- GTLB 2.19
- MACD
- MRNA -0.13
- GTLB 0.16
- Stochastic Oscillator
- MRNA 16.97
- GTLB 75.43
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About GTLB GitLab Inc.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.